Recently Viewed
Clear AllValue Research Rating
Quality Score 
0/0
Growth Score
0/0
Valuation Score
0/0
Momentum Score
0/0
Today’s Range
52 Week Range
Liquidity
Market cap
$467 Mln
Revenue (TTM)
$181 Mln
Net Profit (TTM)
$0 Mln
ROE
0.1 %
ROCE
-- %
P/E Ratio
23.1
P/B Ratio
1.8
Industry P/E
--
EV/EBITDA
11.1
Div. Yield
3.1 %
Debt to Equity
0
Book Value
$4.4
EPS
$0.4
Face value
--
Shares outstanding
57,686,056
CFO
$63.26 Mln
EBITDA
$112.90 Mln
Net Profit
$41.68 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Kamada - ADR
| 20.0 | -2.6 | 20.0 | 26.4 | 22.2 | 6.5 | 8.3 |
|
BSE Sensex
| -13.4 | -9.8 | -13.9 | -3.6 | 7.5 | 7.9 | 11.2 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|
|
Kamada - ADR
| 15.9 | 52.6 | -39.1 | 1.5 | -5.1 | 36.6 |
|
S&P Small-Cap 600
| 4.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 |
|
BSE Sensex
| 9.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Kamada - ADR
|
8.5 | 466.6 | 195.3 | 21.9 | 12.7 | 8.3 | 23.1 | 1.8 |
| 16.8 | 198.6 | 17.0 | -23.9 | -96.8 | -63.9 | -- | 4.5 | |
| 2.1 | 1.9 | 0.0 | -4.8 | -- | -93.3 | 0 | 0.2 | |
| 4.4 | 80.3 | 0.0 | -34.2 | -- | -366.3 | -- | 7.2 |
Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its products include KAMRAB/KEDRAB indicated as prophylaxis of rabies; CYTOGAM for prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung... transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; and Echis coloratus and Vipera palaestinae Antiserum to treat snake bite. The company also distributes biopharmaceutical products in Israel, including BRAMITOB to manage chronic pulmonary infection; FOSTER to treat asthma; TRIMBOW for chronic obstructive pulmonary disease; PROVOCHOLINE for the diagnosis of bronchial airway hyperactivity; AEROBIKA, an OPEP device; RUPAFIN and RUPAFIN ORAL SOLUTION for allergic rhinitis and Urticaria; SINTREDIUS for rheumatoid arthritis, systemic lupus erythematosus, and mild-moderate juvenile dermatomyositis; IVIG for various immunodeficiency-related conditions; VARITECT for chicken pox and zoster herpes; ZUTECTRA and HEPATECT CP for prevention of hepatitis B; MEGALOTECT CP for CMV virus; RUCONEST for angioedema attack; HEPARIN SODIUM INJECTION for thrombo-embolic disorders and prophylaxis of deep vein thrombosis and thromboembolic events; ALBUMIN and ALBUMIN for blood plasma; Factor VIII for hemophilia type A; and Factor IX for hemophilia type B. In addition, it distributes COAGADEX to treat hereditary factor X deficiency; IXIARO for Japanese encephalitis; VIVOTIF for salmonella typhi; PROCYSBI for nephropathic cystinosis; LAMZEDE for alpha-mannosidosis; RYPLAZIM for hypoplasminogenemia; ELIGARD for prostate cancer; and BEVACIZUMAB KAMADA for various cancers. The company was incorporated in 1990 and is headquartered in Rehovot, Israel. Address: 2 Holzman Street, Rehovot, Israel, 7670402 Read more
Chief Executive Officer
Mr. Amir London
Chief Executive Officer
Mr. Amir London
Headquarters
Rehovot
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Kamada Ltd - ADR is $8.47 (NASDAQ) as of 02-Apr-2026 16:00 EDT. Kamada Ltd - ADR has given a return of 22.17% in the last 3 years.
The P/E ratio of Kamada Ltd - ADR is 23.06 times as on 31-Mar-2026.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
19.91
|
1.62
|
|
2024
|
22.91
|
1.28
|
|
2023
|
42.46
|
1.44
|
|
2022
|
-77.46
|
1.02
|
|
2021
|
-134.36
|
1.69
|
The 52-week high and low of Kamada Ltd - ADR are Rs 9.35 and Rs 5.54 as of 04-Apr-2026.
Kamada Ltd - ADR has a market capitalisation of $ 467 Mln as on 31-Mar-2026. As per SEBI classification, it is a Small Cap company.
Before investing in Kamada Ltd - ADR, assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.